tiprankstipranks
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
US Market
AXSM
Axsome Therapeutics
RESEARCH TOOLSreports

Axsome Therapeutics (AXSM) Stock News & Sentiment

2,347 Followers
Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating
Premium
Ratings
Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating
4d ago
AXSM
Axsome acquires global rights to Takeda’s balipodect
Premium
Company Announcements
Axsome acquires global rights to Takeda’s balipodect
12d ago
8K
AXSM
3 Best Growth Stocks to Buy This Week, According to Analysts – March 16-20
Premium
Market News
3 Best Growth Stocks to Buy This Week, According to Analysts – March 16-20
28d ago
WIX
AXSM
Axsome Therapeutics: Strong AUVELITY/SUNOSI Momentum and Rich Late-Stage Pipeline Underpin Buy Rating
Premium
Ratings
Axsome Therapeutics: Strong AUVELITY/SUNOSI Momentum and Rich Late-Stage Pipeline Underpin Buy Rating
2M ago
AXSM
Axsome Therapeutics: Auvelity Growth and Alzheimer’s Agitation Upside Support Buy Rating and $214 Target
Premium
Ratings
Axsome Therapeutics: Auvelity Growth and Alzheimer’s Agitation Upside Support Buy Rating and $214 Target
2M ago
AXSM
Axsome Therapeutics Signals Strong Growth in Earnings Call
Premium
Company Announcements
Axsome Therapeutics Signals Strong Growth in Earnings Call
2M ago
AXSM
Axsome Therapeutics: Buy Rating on Solid Execution, Sufficient Cash Runway, and Advancing Late‑Stage Pipeline
Premium
Ratings
Axsome Therapeutics: Buy Rating on Solid Execution, Sufficient Cash Runway, and Advancing Late‑Stage Pipeline
2M ago
AXSM
More AXSM News >

AXSM News on the Web

Why Axsome Therapeutics Stock Is Sinking Today
TipRanks News
Neutral
Axsome Therapeutics price target raised to $259 from $251 at UBS
TipRanks News
Bullish
Axsome Therapeutics: Auvelity’s Best‑in‑Class Potential in Alzheimer’s Agitation Supports Buy Rating
TipRanks News
Bullish
Why Axsome Therapeutics Stock Is Suddenly Sinking
TipRanks News
Bearish
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
TipRanks News
Bullish
Is This Healthcare Stock a Millionaire Maker?
The Motley Fool
Neutral
Axsome Therapeutics Sets May 4 Release for Q1 2026 Results—Investors Await Updates on CNS Drug Pipeline
Market Chameleon
Neutral
Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
TipRanks News
Neutral

News Score - Last 7 Days

Positive
AXSM
Sector Average
Media Buzz
This Week8 articles
Weekly Average5.75 articles
News Sentiment
This Week80%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is AXSM’s Media Buzz Sentiment?
8 articles about AXSM were published this week. In an average week, 5.75 articles are published.
    What is AXSM’s weekly average amount of articles?
    In an average week, 5.75 articles about AXSM are published.
      What is AXSM’s News Sentiment?
      80% of articles about AXSM were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        STAAStaar Surgical
        IVVDInvivyd
        SLPSimulations Plus
        REPLReplimune Group
        Showing the stocks with the most bullish news sentiment over the past week